VIDAC PHARMA HOLDING PLC
Commented by Nico Popp on July 23rd, 2026 | 07:40 CEST
The Patent Cliff Could Cost Billions: How Bayer and Merck & Co. Respond—and How Vidac Pharma Is Gaining Momentum
Leading oncology centers have long recognized that the fight against cancer cannot be won with just one active ingredient. It is increasingly clear that lasting treatment success depends on combining multiple therapeutic approaches. For years, oncologists relied heavily on conventional chemotherapy. Yet tumours consistently prove resilient and demand more complex therapies. Since patents on many active ingredients are expiring anyway, new, complementary forms of therapy are gaining prominence. One of these therapies targets the disrupted energy metabolism of cancer cells and shows promise. We examine the market and introduce an exciting biotech company that few experts are familiar with.
Read
Commented by André Will-Laudien on July 15th, 2026 | 11:00 CEST
Sharp Swings in the Life Sciences Sector: Bayer, Vidac Pharma, BioNTech, Moderna, and Evotec in the Spotlight
Things are really heating up here! Cancer research is currently undergoing a historic turning point thanks to the convergence of cell analysis and digital precision. With a new management team, BioNTech is attempting to transition its revolutionary mRNA platform from COVID-19 to personalized cancer vaccines, while Bayer is strategically focusing on next-generation targeted radionuclide therapies. In the agricultural sector, the first signs of relief are finally emerging, as glyphosate is now being negotiated at the supranational level and has been classified as non-harmful by US authorities. At the same time, drug discovery company Evotec is grappling with a new revenue warning—and this one is particularly severe. Vidac Pharma is also coming into focus as a highly specialized innovator by blocking cancer metabolism to decisively manipulate the tumour microenvironment. These four distinct approaches impressively demonstrate that the victory over cancer no longer lies solely in traditional chemotherapies, but rather in highly specialized biotech companies and data-driven alliances. With so much news on the table, volatility is sure to follow.
Read
Commented by Nico Popp on July 7th, 2026 | 07:35 CEST
Pulling the Plug on Cancer: Agios Pharmaceuticals, Revolution Medicines, and Vidac Pharma
Without health, everything else is nothing. In recent years, companies in the pharmaceutical and biotech sectors have already achieved major successes when it comes to easing the suffering of the chronically ill and of cancer patients. Progress is increasingly being made thanks to innovative platform approaches that make it possible to combine different technologies. One example is thermodynamic and metabolic platforms. We examine the latest trends and explain how investors can also benefit from innovations in biotechnology.
Read
Commented by André Will-Laudien on June 29th, 2026 | 07:30 CEST
AI and M&A Frenzy in the Life Sciences Sector: Bayer, Vidac Pharma, Novo Nordisk, Evotec, and Eli Lilly
Yes, you read that correctly. Pharmaceutical companies are actively embracing artificial intelligence (AI) and, thanks to lower costs, better validation, and faster study setups, could emerge as winners of the new AI wave in the medium term. Many stocks in the life sciences sector had been overlooked by the market, but investors are now taking notice again. Eli Lilly is betting on AI and expanding its portfolio through targeted acquisitions, including the takeovers of sleep-wake specialist Centessa Pharmaceuticals and blood cancer specialist Ajax. At Evotec and Vidac Pharma, much of the focus is on cancer, while Novo Nordisk faces stiff competition from Eli Lilly's weight-loss drugs. Then came the welcome news regarding Bayer. The Supreme Court ruled that approximately 181,000 individual lawsuits alleging a lack of warning labels on packaging are no longer legally viable, as the US Environmental Protection Agency (EPA) has classified the herbicide glyphosate as safe. Lots of good news, and plenty of opportunities for active investors - we provide a few insights.
Read
Commented by Armin Schulz on June 24th, 2026 | 08:30 CEST
Cancer remains the hottest bet in the pharmaceutical market: Bayer, Vidac Pharma, and Pfizer are competing for the next generation of therapies
The oncology market is the most dynamic segment of the pharmaceutical industry. While global heavyweights are positioning their multibillion-dollar pipelines, a small biotech company is banking on a scientific approach that directly targets the metabolism of tumour cells. For investors, the key question is whether the future of cancer treatment will be defined by broad-based therapies, targeted antibody-drug conjugates, or precise interventions at the cellular metabolic level. The differing approaches taken by Bayer, Vidac Pharma, and Pfizer promise to set the course not only medically but also financially for the coming decade.
Read
Commented by Nico Popp on June 18th, 2026 | 07:35 CEST
The Secret Mechanism That Kills Cancer Cells: What Revolution Medicines and Merck & Co. Need to Learn from Vidac Pharma
There is, without exaggeration, a looming "patent cliff" of enormous scale: an estimated USD 236 billion in annual revenue losses are forcing the biopharmaceutical industry to find new paths forward. Pharma giants must replace dwindling blockbuster revenues by strategically acquiring innovative oncology platforms, as conventional cancer therapies are increasingly reaching their limits. This innovation pressure is triggering a consolidation wave in which research-driven biotech companies with protected mechanisms of action are moving into the center of potential takeover activity. In particular, intracellular and metabolic treatment approaches are rapidly gaining importance in the fight against treatment-resistant cancers. We take a look at Revolution Medicines' successes and identify the next potential high-flyer.
Read
Commented by Tarik Dede on June 11th, 2026 | 07:05 CEST
Wave of Biotech Acquisitions: Eli Lilly, Vidac Pharma, and GSK in the Spotlight
Cancer remains one of humanity's greatest scourges, and at the same time, it is by far the largest healthcare market of all. But the old-school pharmaceutical giants are running out of oncology pipeline candidates, and now smaller, far more innovative players are increasingly being acquired. The M&A market is currently experiencing extremely dynamic times. This week, for example, GSK announced the acquisition of Nuvalent for USD 10.6 billion in cash. Gilead Sciences, in turn, struck a deal in April with the German company Tubulis—for a total of USD 5 billion. Shortly thereafter, Eli Lilly offered up to USD 7 billion for Kelonia Therapeutics, just to name a few of this year's deals. That is why we are taking a look at the opportunities in the sector today and putting the stocks of Eli Lilly, Vidac Pharma, and GSK under the microscope!
Read
Commented by Armin Schulz on June 3rd, 2026 | 07:25 CEST
Opportunities in the Oncology Market: Positioning for the Next Billion-Dollar Catalyst with BioNTech, Vidac Pharma, and Pfizer
An aging population is driving rapid increases in healthcare spending. A trillion-dollar market is emerging in the cancer sector, as over 30 million new cases are expected annually by 2040. As traditional chemotherapy approaches its limits, new technologies and ideas are needed. Those who set the course today can benefit from this transformation, even if not every approach will succeed. The key question remains: which companies possess the key technologies to benefit from this boom? Three players are coming into particular focus: BioNTech with its mRNA platform, Vidac Pharma with a patented metabolic approach, and Pfizer with its multi-billion-dollar acquisitions.
Read
Commented by Fabian Lorenz on May 26th, 2026 | 07:30 CEST
Caution with BioNTech! Novo Nordisk Accelerates! Buying Opportunity in Vidac Pharma Stock?
Investor sentiment around Novo Nordisk is improving. Shares of the Danish pharmaceutical giant appear to be breaking out of the downtrend that began in the summer of 2024, with investors responding positively to recent developments. At Vidac Pharma, the latest announcement seems to have gone largely unnoticed. Yet it could mark the beginning of interest from strategic investors. There is even speculation about a potential full takeover of the oncology specialist. With a market capitalization of only around EUR 33 million, any acquisition would likely require a substantial premium. While investors may be knocking on Vidac's door, sentiment toward BioNTech has deteriorated. The company's founding couple is stepping down, and locations are being closed. And now analysts are also questioning the quality of the company's product pipeline.
Read
Commented by André Will-Laudien on May 21st, 2026 | 07:10 CEST
Undervalued – Analysts Turn Their Attention to Life Sciences: Bayer, Vidac Pharma, Novo Nordisk, and Pfizer in Focus
DZ Bank's aggressive price target adjustment for Bayer demonstrates that analysts have recently begun to view the life sciences sector more favourably. The pharmaceutical and agrochemical group's strong start to the year has led to significantly improved prospects, and legal risks are now also viewed as more moderate. Finally, some good news for long-suffering investors in a geopolitically volatile environment. After all, there have not been any major upgrades in the sector for quite some time. When it comes to Novo Nordisk, however, experts remain divided on whether the earnings trend will turn positive again. Cutthroat competition in the weight-loss drug market is intense, putting pressure on margins. Buoyed by industry sentiment, Pfizer also saw its stock rise again. Time for a new tour of the sector. Where are the triggers?
Read